康柏西普不同注药方案治疗视网膜疾病的研究进展

Research Progress on Different Injection Regimens of Conbercept in the Treatment of Retinal Diseases

摘要: 血管性视网膜疾病是一种以视网膜出血渗出、血管异常增殖等为主要特征的疾病，黄斑水肿是其最常见也是主要影响视力的并发症，糖尿病视网膜病变(diabetic retinopathy, DR)、视网膜静脉阻塞(retinal vein occlusion, RVO)、年龄相关性黄斑变性(age-related macular degeneration, AMD)等患者常因合并黄斑水肿后于医院就诊。视网膜血管性疾病的发生和发展与抗血管内皮生长因子(vascular endothelial growth factor, VEGF)的显著增高密切相关，因此，抗VEGF药物应运而生，凭借其能使新生血管快速消退、减少渗漏、促进积血吸收等优点，被广泛用于治疗各种血管性视网膜疾病，在抗VEGF药物中，目前国内多采用康柏西普治疗视网膜血管性疾病，并取得了一定效果，但长期疗效有待进一步研究。同时，个体化差异使得康柏西普疗效不同。所以个体化治疗方案将会给康柏西普在眼科中的临床应用带来更广阔的前景。

Abstract: Vascular retinal disease is a disease characterized by retinal hemorrhage, exudation, abnormal pro-liferation of blood vessels, and macular edema is the most common complication that mainly affects vision. Diabetes retinopathy (DR), retinal vein occlusion (RVO) patients with age-related macular degeneration (AMD) often seek medical attention after experiencing visual impairment due to the presence of macular edema. The occurrence and development of retinal vascular diseases are closely related to the significant increase of anti vascular endothelial growth factor (VEGF). There-fore, anti VEGF drugs have emerged, which are widely used in the treatment of various vascular retinal diseases due to their advantages of quickly subsiding neovascularization, reducing leakage, and promoting blood absorption. Among anti VEGF drugs, at present, Conbercept is widely used in the treatment of retinal vascular diseases in China and has achieved certain results, but the long-term efficacy needs further research. At the same time, individualized differences result in different therapeutic effects of Conbercept. So personalized treatment plans will bring broader prospects for the clinical application of Conbercept in ophthalmology.